MUC1 and interstitial lung disease: Several other groups have described that dynamic change in serum KL-6 levels appears to reflect disease patterns and may be a marker of therapeutic efficacy or disease progression in other fibrotic interstitial lung diseases [7, 25, 26], thus implicating KL-6 as a potential biomarker for longer term sequelae of COVID-19.